



45 Vogell Road, Suite 200, Richmond Hill, Ontario, Canada L4B 3P6
Phone: 905-770-3711 Fax: 905-770-4811 www.ppcdrugs.com

October 13, 2009

Dear PPC Heparin Customer:

As a proven leader in providing safe, efficacious and rigorously tested Heparin products, we wanted to inform you of important changes to the United States Pharmacopeia (USP) monograph for unfractionated heparin and the steps PPC is taking to ensure a smooth transition.

On October 1, 2009, the implementation of the new USP monograph for unfractionated heparin went into effect. The purpose of the USP monograph changes are to further assure the continuing purity of the Active Pharmaceutical Ingredient (API) through specific assay tests and to calibrate activity to align with the International Standard (IS) issued by the World Health Organization (WHO). It is anticipated that finished product prepared with the new International Standard will demonstrate a decrease in potency of approximately 10% compared to product made under the previous USP standard.

PPC has always met or exceeded USP standards and will implement and meet the new USP standards. However, based upon our existing inventory hold and demand, **we do not anticipate product manufactured under the new standard to be distributed in Canada until early in 2010. This product will be differentiated by the placement of the letter "N" after the lot number.** We will be notifying all customers one month prior to distribution of the first code manufactured under the new standard.

To support the medical community's understanding, and readiness for a new USP monograph change for unfractionated heparin and the introduction of new USP Reference Standards (RS), our parent company, APP Pharmaceuticals has launched an educational webinar series with industry experts that is available on their website at: www.apppharma.com. In addition, a list of questions and answers on this subject is provided on our website at: www.ppcdrugs.com.

Additional information is available at the following links for the US Food and Drug Administration (FDA) at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm184674.htm> and for the USP at: <http://www.usp.org/hottopics/heparin.html>

While we will continue to post copies of all communications that are distributed on our website, we would ask that you forward this correspondence to all other departments that may be affected by this change in your hospital. Be aware that there will be a period of time when product manufactured under the old and new USP standard will simultaneously be on the market.

For clinical and technical questions regarding PPC products, please call Medical Information at 1-877-779-7760 between the hours of 8:30 a.m. and 4:30 p.m. ET. In addition, customers will be able to find up-to-date product information and webinar registration and other pertinent information on our website: www.ppcdrugs.com

PPC continues to be committed to you, our customers, and to providing safe products you can trust.

Sincerely,

Jim Walker
VP Scientific Affairs

Visit our website at www.ppcdrugs.com